about
A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data.Predictors of high-risk prescribing among elderly Medicare Advantage beneficiariesPerformance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies.Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillanceDevelopment and Validation of an Index to Predict Personal Prescription Drug Importation by Adults in the United StatesHepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims databaseUnderreporting high-risk prescribing among Medicare Advantage plans: a cross-sectional analysisDisparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert.Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomeNational Trends in Treatment Initiation for Nursing Home Residents With Diabetes Mellitus, 2008 to 2010Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial.Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus.A cohort study of acute pancreatitis in relation to exenatide use.Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents.Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users.Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured US populations.Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain.Association of β-Blockers With Functional Outcomes, Death, and Rehospitalization in Older Nursing Home Residents After Acute Myocardial Infarction.Beta-Blocker Use in U.S. Nursing Home Residents After Myocardial Infarction: A National Study.Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with type 2 diabetes mellitus.Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States.Prescriber and pharmacy variation in patient adherence to five medication classes measured using implementation during persistent episodes.The effect of labour induction on the risk of caesarean delivery: using propensity scores to control confounding by indication.Implications of immortal person-time when outcomes are nonfatal.Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users.National Glucose-Lowering Treatment Complexity Is Greater in Nursing Home Residents than Community-Dwelling Adults.Understanding drug effects in older people: the role of pharmacology--reply.Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care.Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration.Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.Secondary Prevention Medication Use After Myocardial Infarction in U.S. Nursing Home Residents.A pooled analysis of exenatide use and risk of acute pancreatitis.Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.Age, Sex, and Dose Effects of Nonbenzodiazepine Hypnotics on Hip Fracture in Nursing Home Residents.A day in the life of a corporate retail pharmacist.Safety study of live, oral human rotavirus vaccine: A cohort study in United States health insurance plans.Predictive values of diagnostic codes for identifying serious hypocalcemia and dermatologic adverse events among women with postmenopausal osteoporosis in a commercial health plan database.Is there an association between liraglutide use and female breast cancer in a real-world setting?Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarctionUse of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
P50
Q30780789-C9AA7C42-0D6B-4392-81C0-60E8A5B1C86CQ33596373-B59D74DC-3D03-4784-9A48-62F99F1296BEQ33644714-A842BF25-2219-465F-8CC5-9042A1FF5F1AQ33949418-0CDF0111-2B8B-4FAA-88F1-B87781653B1DQ34532841-C1AD370A-1A90-4F5D-B133-469FE1C24C07Q35807663-B0F61378-F7F9-4F40-A5AF-DA675F0BE351Q36484625-4B5FC8DA-9F29-449E-B590-6D1A0B4685D7Q36728428-F51AAD04-177D-40B2-9675-4507E1DAB352Q37019516-D4858242-DCD3-488B-AE42-EEB517BF293EQ37048008-0581BD7E-3117-4E20-B354-45C37BDAA509Q37167232-DA0EEA35-4C14-4DBF-B4EC-524F3DC7174FQ37831268-5B4C0AD6-42F7-4FDE-93EA-A6F1220080DBQ37841739-F5576961-6F21-422B-B0DF-926703E3819EQ38694106-A9B5E902-9C27-4FF7-925D-A2D736209CEDQ38789945-C0A75FF9-9C69-40E0-9E24-2B887D531C72Q38953381-B64C09A3-9C08-4D7D-B63B-45E39065EF09Q38960798-E10C8265-C9DB-453C-8B6E-34EE6EE26486Q39109485-3C220F16-1118-4FE9-B90C-380732669015Q39175816-B110CE17-BB57-435C-AB73-6E947BF35BBBQ39288074-EA9F97F1-7F9D-4A7F-AFC2-6E8032100ACFQ39308511-39E114C2-550D-4268-906F-7BFF220A76D4Q39770404-85E3D668-DF14-4BB2-8622-549F282DF6F0Q40494633-C9307959-7189-46F4-85AD-E811CB66190BQ40928980-02FA90B3-21A9-489A-A143-E6DEDCDD0A4DQ43095242-5D3D3E98-14FD-40D5-BE2C-922FC6364E48Q44318371-88E03499-1F84-4DE1-B71D-19016743473CQ45323938-5F3CC383-F722-4BFA-AC61-723A231DCA88Q45326482-166A2A5F-A487-492F-8520-84AC21769A03Q45330418-AA52E1FE-00C3-4CAA-B946-D21A2A27973AQ45340352-90704CAA-8BCF-4A74-9238-BBA404354904Q46101602-A84C34AF-6283-48A8-BB80-036DF471F824Q46963914-B4A358EF-049E-415D-9C48-100915083FE5Q47386231-9A26D71C-F539-492F-AD9E-C3381509941FQ47615989-CF77F260-702F-48FD-BB50-45CB31CE88C6Q48388478-1ADA0FE9-4119-49B9-B1A0-9AEC44AFD0BAQ52658436-F290FE04-71B9-4351-ADBC-D820B89F7887Q55027036-BB67D61D-D3EF-4456-B8CC-A49D72C756F1Q59812883-FD216B01-047C-4438-A7D5-BDE150E0BFCEQ60114952-F113A89D-02E9-4723-89C1-D9DE8152B068Q61836852-8B4A63AA-5B6C-435C-9EF1-B9BF66C3B741
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
David D Dore
@en
David D Dore
@nl
type
label
David D Dore
@en
David D Dore
@nl
prefLabel
David D Dore
@en
David D Dore
@nl
P31
P496
0000-0003-0810-6662